{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-004643","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2024-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.374548+00:00","generated_at":"2026-06-06T10:15:31.258901+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"FibroBiologics begins trading on Nasdaq via direct listing under ticker FBLG","bullets":["Direct listing commenced January 31, 2024 on the Nasdaq Global Market.","Stock trades under ticker symbol FBLG.","Company is a clinical-stage biotech focused on fibroblast-based therapies for chronic diseases.","Registration statement on Form S-1 declared effective by SEC on January 24, 2024.","No financial results or operational milestones were disclosed in the announcement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-004643","json":"https://secwatch.observer/filing/0001493152-24-004643.json","markdown":"https://secwatch.observer/filing/0001493152-24-004643.md","text":"https://secwatch.observer/filing/0001493152-24-004643.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224004643/0001493152-24-004643-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224004643/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T10:15:31.258901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}